UroGen Q2 2026 Earnings: ZUSDURI Launch Nearly Triples Revenue

UroGen Pharma (Nasdaq: URGN) reported Q2 2026 revenue of $72.5 million, up approximately 199% from $24.2 million a year earlier, while basic and diluted net loss per share narrowed to $0.28 from $1.05. ZUSDURI generated $50.4 million during its commercial launch, helping UroGen reach a small operating profit even as financing, interest and tax expenses kept the company in a net loss.

Core financial results

For the quarter ended June 30, 2026, UroGen’s revenue nearly tripled as ZUSDURI added a second commercial product alongside JELMYTO. Gross profit increased faster than operating expenses, moving the company from a $41.4 million operating loss to $0.1 million of operating income.

R&D expense declined because the year-earlier quarter included ZUSDURI manufacturing costs recorded before FDA approval. SG&A increased due to the expanded ZUSDURI sales force, brand marketing and other commercial activities.

All figures are GAAP results. The company did not report adjusted earnings or cash-flow metrics in the supplied quarterly results.

Product performance and pipeline

ZUSDURI drove the revenue expansion

ZUSDURI produced $50.4 million of net product revenue, representing 73% sequential growth from Q1 2026. As of June 30, UroGen had 1,444 activated sites of care and 452 unique prescribers. Repeat prescribers reached 204, or approximately 45% of all prescribers, compared with 40% in the preceding quarter.

The updated Phase 3 ENVISION results showed an estimated 36-month duration-of-response rate of 64.5% among patients who achieved a complete response at three months. The three-month complete response rate was 79.6%, and median duration of response had not been reached after a median follow-up of 35.5 months.

UroGen also received a Notice of Allowance for a U.S. patent covering certain treatment methods. Once issued, the patent is expected to protect ZUSDURI and UGN-103 into July 2044.

JELMYTO revenue declined

JELMYTO generated $22.0 million, down approximately 9% from $24.2 million in Q2 2025. UroGen nevertheless maintained its full-year revenue guidance for the product.

The company also settled its JELMYTO patent litigation with Teva. The agreement grants Teva a non-exclusive license to sell an FDA-approved generic version beginning September 15, 2030, subject to limited customary exceptions.

Near-term development milestones

UGN-103 recorded an estimated six-month duration-of-response rate of 94.5% in the Phase 3 UTOPIA trial, compared with 91.9% for ZUSDURI in ENVISION. UroGen remains on track to submit an NDA for UGN-103 in Q3 2026 and plans to begin a Phase 3 study in high-risk non-muscle invasive bladder cancer during the second half of 2026.

The Phase 3 UGN-104 trial remains on track to complete enrollment by the end of 2026. The FDA has also accepted the investigational new drug application for UGN-501, with its Phase 1 trial scheduled to begin in Q4 2026.

ZUSDURI brought operating break-even, but financing costs kept earnings negative

Revenue increased by approximately $48.2 million year over year, while gross profit rose by about $45.2 million and total operating expenses increased by only $3.7 million. That operating leverage produced a roughly $41.6 million improvement in operating income and moved the operating margin from approximately negative 171% to slightly positive.

The operating result did not translate into net profitability. UroGen recorded $4.5 million of non-cash financing expense related to its prepaid forward obligation, $4.9 million of long-term debt interest expense and $5.6 million of income tax expense. Interest expense increased after the company borrowed an additional $75.0 million during its Q1 2026 debt refinancing, partly offset by a lower interest rate.

Cash, cash equivalents and marketable securities totaled $108.0 million at June 30, down from $120.5 million at December 31, 2025. Over the same period, total liabilities increased from $305.9 million to $385.0 million, while the shareholders’ deficit widened from $105.5 million to $132.4 million.

2026 guidance

UroGen maintained JELMYTO revenue guidance but raised operating-expense guidance. The higher spending plan reflects additional ZUSDURI physician education and patient-awareness initiatives, as well as accelerated work on the UGN-103 high-risk trial and UGN-501 development.

UroGen did not provide full-year ZUSDURI revenue guidance because the product remains in the early stages of its commercial launch.

Recent insider transactions

The supplied insider dataset shows 29,500 shares purchased and 42,701 shares sold over the last six months, resulting in net sales of 13,201 shares, or 0.70% of total insider holdings. Total insider shares held were reported at approximately 1.76 million.

Among the latest entries, six transactions included both an explicit sale designation and a reported value. The data do not provide enough information to infer the insiders’ reasons for selling.

Risks investors should monitor

• Early-stage ZUSDURI launch: ZUSDURI accounted for about 70% of quarterly revenue, but UroGen has not provided full-year guidance for the product. Future results depend on sustained prescriber adoption, repeat use and reimbursement coverage.
• Higher spending and balance-sheet obligations: Operating-expense guidance was raised while UroGen remained loss-making on a net basis. Cash declined from year-end, liabilities increased, and interest expense rose following additional borrowing.
• Clinical and regulatory execution: The timing and outcome of the UGN-103 NDA, UGN-104 enrollment and UGN-501 Phase 1 initiation remain subject to clinical and regulatory uncertainty.
• Intellectual-property and competition exposure: The new ZUSDURI and UGN-103 patent has been allowed but not yet issued. Separately, the Teva settlement permits a potential JELMYTO generic launch beginning in September 2030 if approved.

Summary

UroGen’s Q2 2026 results show that ZUSDURI has materially changed the company’s revenue and operating profile, lifting gross margin and bringing quarterly operations close to break-even. The next tests are whether adoption remains durable as commercial investment rises, whether the balance sheet can support continued losses and pipeline spending, and whether UGN-103 and the rest of the clinical portfolio meet their upcoming milestones.